A5004019722- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Immune cells in cancer
- Acute Myeloid Leukemia Research
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Epigenetics and DNA Methylation
- RNA Interference and Gene Delivery
- Chronic Lymphocytic Leukemia Research
- Inflammatory Biomarkers in Disease Prognosis
- Chemokine receptors and signaling
- CAR-T cell therapy research
- Cancer, Stress, Anesthesia, and Immune Response
- Hematological disorders and diagnostics
- Polyomavirus and related diseases
- Endometrial and Cervical Cancer Treatments
- Inflammatory Myopathies and Dermatomyositis
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
The University of Texas Southwestern Medical Center
2017-2025
Southwestern Medical Center
2019-2024
The University of Texas MD Anderson Cancer Center
2017
Acquired resistance (AR) is a major limitation of immune checkpoint inhibitor (ICI) therapy when treating renal cell carcinoma (RCC). Understanding who will get AR currently unknown. We hypothesized the T-cell-inhibitory glycoprotein non-metastatic melanoma protein B (GPNMB) to be prognostic marker for patients with AR. Alongside other markers, GPNMB was measured in blood RCC (n = 39) several times after starting ICI treatment and analyzed association Response Evaluation Criteria Solid...
Background Increased body mass index (BMI) has been associated with improved response to immune checkpoint inhibitors (ICIs) in multiple cancer types. We evaluated associations between BMI, ICI dosing strategy, and clinical outcomes. Methods abstracted data on patients treated ICI, including age, sex, type, strategy (weight-based or fixed), radiographic response, overall survival (OS), progression-free (PFS). compared outcomes low-BMI high-BMI populations using Kaplan-Meier curves, Cox...
Antibiotic administration is associated with worse clinical outcomes and changes to the gut microbiome in cancer patients receiving immune checkpoint inhibitors (ICI). However, effects of antibiotics on systemic function are unknown. We, therefore, evaluated antibiotic exposure, therapeutic responses, multiplex panels 40 serum cytokines 124 antibodies at baseline six weeks after ICI initiation, p < 0.05 false discovery rate (FDR) 0.2 considered significant. A total 251 were included, whom...
5569 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved overall survival in Stage III epithelial ovarian cancer (EOC) patients. We set out to evaluate the gene signatures HIPEC response EOC Methods: Ninety-one patients who underwent pre-operative tumor samples at City of Hope (51) and CHU Lyon (40) were identified between 2014 2022. RNA isolation was performed from formalin-fixed paraffin-embedded samples, followed by Whole-transcriptome library...
Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification biomarkers distinguishing responders and nonresponders will improve management Because the DC-HIL differs from PD1 pathway in expression inhibitory mechanisms, we examined whether regulates ICI responsiveness.Plasma samples were collected advanced non-small cell lung carcinoma (NSCLC) (n = 76) at baseline and/or follow-up after monotherapy. Blood-soluble (sDC-HIL) was determined...
Immune-related adverse events induced by immune checkpoint inhibitor (ICI) therapy may affect diverse organ systems, including skeletal and cardiac muscle. ICI-associated myositis result in substantial morbidity occasional mortality. We present a case of patient with advanced non-small cell lung cancer who developed grade 4 concurrent myocarditis early after initiation anti-programmed death ligand 1 (durvalumab). Autoantibody analysis revealed marked increases...
Abstract Background Historically, tumor burden has been considered an impediment to efficacy of immunotherapeutic agents, including vaccines, stem cell transplant, cytokine therapy, and intravesical bacillus Calmette-Guérin. This effect attributed hypoxic zones in the core contributing poor T-cell infiltration, formation immunosuppressive stromal cells, development therapy-resistant populations. However, association between immune checkpoint inhibitors is unknown. We sought determine...
Abstract The value of event-free survival (EFS) as an end point in acute myeloid leukemia (AML) trials has been questioned. We hypothesized that rather than a surrogate for overall (OS), improvement EFS may decrease the use health care. In this retrospective study, we identified 400 patients with AML who were treated on first-line therapy and had OS between 2 36 months. captured care from diagnosis until death or patient was censored at stem cell transplantation (SCT). used correlation...
Abstract Immune checkpoint inhibitor (ICI) therapy has shown unprecedented results in RCC treatment, but durable responses have been hampered by acquired resistance (AR, initially respond eventually develop cancer progression). Mechanisms for AR remain ambiguous. Previously, we reported elevated blood GPNMB to strongly associate with development. To study molecular mechanisms AR-linked elevation, created an ICI-resistant RenCa (R-RenCa) mouse model repeated selection of largest tumors mice...
A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of treatment initiation, thereby providing information prior to efficacy assessment. Although immune checkpoint inhibitor (ICI)-associated immune-related adverse events (irAE) have been associated with therapeutic benefit, irAE may delayed highly variable...
<h3>Background</h3> Clinically actionable biomarkers of immune checkpoint inhibitor (ICI) response are currently limited to specific mutation profiling, immunohistochemistry staining for PD-L1, and tumor mutational burden. Use the latter two challenging, as they incompletely predictive lack accepted standards measurement interpretation. Transcriptomic associations with have been reported may add critical information an integrated biomarker strategy. There is a need better understanding...
<p>Figure S1, Figure S2, S3, S4, S5, S6, S7, S8, Table S3</p>
<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification biomarkers distinguishing responders and nonresponders will improve management Because the DC-HIL differs from PD1 pathway in expression inhibitory mechanisms, we examined whether regulates ICI responsiveness.</p>Experimental Design:<p>Plasma samples were collected advanced non–small cell lung carcinoma (NSCLC) (<i>n</i> = 76)...
<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification biomarkers distinguishing responders and nonresponders will improve management Because the DC-HIL differs from PD1 pathway in expression inhibitory mechanisms, we examined whether regulates ICI responsiveness.</p>Experimental Design:<p>Plasma samples were collected advanced non–small cell lung carcinoma (NSCLC) (<i>n</i> = 76)...
<p>Figure S1, Figure S2, S3, S4, S5, S6, S7, S8, Table S3</p>
Combination pembrolizumab with lenvatinib (len/pem) has revolutionized second-line treatment and survival outcomes for patients mismatch repair-proficient (MMRp) recurrent endometrial cancer (EC). We sought to define existing barriers medication access and, through quality improvement (QI) techniques, improve decrease healthcare disparities in a high risk, medically underserved population. Following IRB approval, we identified all MMRp EC dispositioned receive len/pem our institution....
Immunotherapy (IO), either as single agent or in combination (ex: pembrolizumab +/– lenvatinib), is a critical tool the treatment of advanced/metastatic endometrial cancer (EC). In other tumor types, incidence immune related adverse events (irAEs) correlates with improved outcomes, however this has never been fully explored (EC); we sought to explore real-world irAEs and efficacy IO EC. Following IRB approval, reviewed all patients EC receiving our institution. Clinico-demographic data were...
e14038 Background: Anti-PD1/PDL1 therapy benefits only a minority (10-20%) of treated NSCLC. Identifying markers distinguishing responders vs. non-responders will improve management DC-HIL receptor is new checkpoint whose inhibitory mechanisms are divergent from the PD1 pathway. Tumor cells express and its soluble form (sDC-HIL). We tested whether sDC-HIL expression regulates NSCLC response to anti-PD1/PDL1 Ab using animal models human clinical samples. Methods: Tet-Off controlled...
e18513 Background: EFS is not considered a robust end-point for AML trials. We hypothesized that rather than surrogate overall survival (OS), improvement in may be valuable due to patients (pts) staying remission and thus decreasing health care utilization (HCU). Methods: In this retrospective study we identified pts treated on frontline therapy trials at our institute from 2003-2013 with ≥2 months (mo) OS of 12-36 mo. captured the amount HCU diagnosis till death, including number clinic...
<h3>Background</h3> Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, long-term benefits are only achieved in a small fraction of patients. Understanding the mechanisms underlying ICB activity is key to improving efficacy immunotherapy. A major limitation uncovering these limited number responders within each trial. Integrating data from multiple studies would help overcome this issue and more reliably define immune landscape durable responses. Towards goal, we...
e15126 Background: The mechanisms by which immune checkpoint inhibitors (ICI) cause related adverse events (irAE) are not clear. No current blood tests predict patients will suffer irAEs. Methods: 70 cancer had drawn prior to ICI and then 4-6 weeks later. 63 lung cancer; median age was 69 yrs; 21 were female treatment duration 142 days. Patient samples analyzed using flow cytometry for over 50 lymphoid myeloid markers determine levels of circulating white cells, as well their changes time....